BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com

- September 23rd, 2021

SmallCapVoice.com Inc. announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. to discuss three key achievements that support the Company’s continued growth. BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer. Speaking with SCV’s Stuart Smith, Dr. Williams first detailed the importance of …

SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company’s continued growth.

BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer. Speaking with SCV’s Stuart Smith, Dr. Williams first detailed the importance of BriaCell’s recent collaboration with ImaginAb to evaluate the safety and efficacy of the Company’s immunotherapy treatments in patients with advanced breast cancer.

Dr. Williams also discussed the expansion of BriaCell’s board of directors to include Marc Lustig, an expert in corporate finance and the pharmaceutical industry, as well as the Company’s decision to use its excess capital to repurchase its securities.

“We have over $55 million in the bank and our programs are moving forward,” he said. “We’re in the clinic with a clinical asset that has positive proof of concept data, but our valuation is that of a pre-clinical type of company … We want to show people that we are very serious about moving our stock forward and also getting our capital markets aligned with where we ought to be, in terms of the valuation of the Company.”

The full interview can be heard at: https://www.smallcapvoice.com/interview-briacell-therapeutics-corp-bctx/ .

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://BriaCell.com/

About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/ .

Socialize with SmallCapVoice and their clients at

Facebook: https://www.facebook.com/SmallCapVoice/
Twitter: https://twitter.com/smallcapvoice
Instagram: https://www.instagram.com/smallcapvoice/

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
Info@BriaCell.com

Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
Info@BriaCell.com

Investor Relations Contact:
CORE IR
Investors@BriaCell.com

SmallCapVoice.com
Stuart T. Smith
512-267-2430
Info@SmallCapVoice.com

Source: SmallCapVoice.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe8c4141-d54e-4867-ac51-848adae120da


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Tags

Leave a Reply